In light of the obtained results, we can hypothesize that the failure of ANG-2 in providing boosted BBB crossing and tumor cell uptake of specific nanoformulations can be ascribed to the poor understanding of the connection between the synthetic identity of that specific nanovector and its biological identity more than an intrinsic ANG-2/LRP1 interaction failure. The gene discussed is LRP1; the disease is neoplasm.